---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-019862"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:22:32.003220+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q4 revenue $18.4M (+30% YoY), net loss $11.6M; FY2025 guidance $100-106M

## Summary
- Q4 commercial revenue $18.4M (+30% YoY); gross margin 87.6%.
- Net loss $11.6M ($0.44 loss per share) vs $7.1M loss in Q4 2023.
- FY2025 revenue guidance $100-106M (55-65% growth); expects GAAP profitability in Q4 2025.
- Amended OrbiMed credit agreement; adjusted revenue covenants for 2025-2026; issued warrants for 145,180 shares at $0.01/share.
- FDA clearances: Cohealyx (Dec 2024) and RECELL GO mini (Dec 2024); full Cohealyx launch by April 2025.

## SEC filing metadata
- accession: 0000950170-25-019862
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017025019862/0000950170-25-019862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017025019862/rcel-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-019862
- JSON: https://secwatch.observer/filing/0000950170-25-019862.json
- Plain text: https://secwatch.observer/filing/0000950170-25-019862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.